Results 131 to 140 of about 11,787 (237)

Fruquintinib: Mechanism of Action, Clinical, and Translational Science

Clinical and Translational Science, Volume 19, Issue 10, October 2026.
ABSTRACT Fruquintinib is a highly selective, oral inhibitor of all three vascular endothelial growth factor receptors (‐1, ‐2, and ‐3) that was approved, including in China, the United States, and the European Union, for the treatment of previously treated metastatic colorectal cancer (mCRC).
Xiaofei Zhou, Arvind Dasari, Jin Li, Caly Chien, Qi Dong, Lucy Chen, Lixian Dong, Neeraj Gupta   +7 more
wiley   +1 more source

Harnessing Quantitative Medicine to Advance Oncology Drug Development

Clinical and Translational Science, Volume 19, Issue 10, October 2026.
ABSTRACT Oncology drug development continues to have a high attrition rate despite major advances in therapeutic modalities such as antibody‐drug conjugates, bispecific antibodies, cell therapies, and cancer vaccines. Critical development decisions are often made under substantial uncertainty, creating a need for quantitative approaches that integrate ...
Benjamin Wu, Kenta Yoshida, Pascal Chanu, Chunze Li   +3 more
wiley   +1 more source

A tutorial on physiologically based pharmacokinetic approaches in lactation research

CPT: Pharmacometrics & Systems Pharmacology
In breastfeeding mothers, managing medical conditions presents unique challenges, particularly concerning medication use and breastfeeding practices.
Amita Pansari, Xian Pan, Lisa M. Almond, Karen Rowland‐Yeo   +3 more
doaj   +1 more source

From Real World Data to Real Impact: A Co‐Medication Framework for Lung Cancer to Advance DDI Assessment and Patient‐Centric Drug Development

Clinical and Translational Science, Volume 19, Issue 10, October 2026.
ABSTRACT Lung cancer predominantly affects older adults who already experience comorbidities and are at increased risk of drug–drug interactions (DDIs) due to polypharmacy. Traditional DDI assessments often do not fully capture complex co‐medication patterns observed in real‐world practice due to the risk of introducing confounding factors.
Mareena Biju, HeeJae Choi, Shilpa Madari, Annie Carlisle, Ashish Sharma, Christina Kunz, Fenglei Huang   +6 more
wiley   +1 more source

Accelerating Biologics PBPK Modelling with Automated Model Building: A Tutorial

Physiologically based pharmacokinetic (PBPK) modelling for biologics, such as monoclonal antibodies and therapeutic proteins, involves capturing complex processes, including target-mediated drug disposition (TMDD), FcRn-mediated recycling, and tissue ...
Qier Wu, Felix Stader, Abdallah Derbalah, Tariq Abdulla, Masoud Jamei, Armin Sepp, Iain Gardner, Mailys De Sousa Mendes   +7 more
core   +1 more source

Translational PBPK Modeling and Exposure‐Response Analysis of AT‐RvD1 for Treating Sjögren's Disease

Clinical and Translational Science, Volume 19, Issue 10, October 2026.
ABSTRACT Sjögren's disease (SD) is an autoimmune condition characterized by chronic inflammation and impaired secretory function of the salivary glands (SG). The proresolving lipid mediator AT‐RvD1 restores SG function in SD‐like mice; however, its tissue pharmacokinetics, exposure‐response relationships, and human dose predictions remain poorly ...
Venkata K. Yellepeddi, Kihoon Nam, Frank M. Maslow, Olga J. Baker   +3 more
wiley   +1 more source

Physiologically Based Pharmacokinetic Modeling to Predict Human Starting Dose and Pharmacokinetics for Rocbrutinib. [PDF]

Clin Transl Sci
Wang L, Yang D, Shao R, Chen J, Wang X, Wang Z, Jiang B.   +6 more
europepmc   +1 more source

LAFOV PET as an enabling platform for pharmacokinetics-informed digital twins. [PDF]

Front Med (Lausanne)
Rittmeyer B, Strugari M, Dietrich S, González-Avilés C, Martí-Bonmatí L, Torres Espallardo I.   +5 more
europepmc   +1 more source

Development and Evaluation of Physiologically Based Pharmacokinetic (PBPK) Models of Metoclopramide Across the Lifespan: Translation from Adults to Infants. [PDF]

Pharmaceuticals (Basel)
Shahzad I, Zamir A, Rasool MF, Alshamrani AA, Hussain I, Alqahtani F.   +5 more
europepmc   +1 more source

Development of an isavuconazole physiologically-based pharmacokinetic model for adult and pediatric populations. [PDF]

J Pharmacokinet Pharmacodyn
Choules MP, Desai A, Kovanda LL, Otsuka Y, Brüggemann RJ, Bonate PL.   +5 more
europepmc   +1 more source